Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m2/day, days 1 to 5, of a 28-day cycle until disease progression, unacceptable toxicity, or withdrawal of consent. Response was determined by imaging at weeks 4 and 8, and every 8 weeks thereafter. Improvement in PFS at 4 months was the primary end point. Secondary objectives included overall response rate (ORR), overall survival (OS), and safety and tolerability of veliparib with TMZ. Exploratory objectives included PARP-1 and SLFN11 immunohistochemical expression, MGMT promoter methylation, and circulating tumor cell quantification. Results No significant difference in 4-month PFS was noted between TMZ/veliparib (36%) and TMZ/placebo (27%; P = .19); median OS was also not improved significantly with TMZ/veliparib (8.2 months; 95% CI, 6.4 to 12.2 months; v 7.0 months; 95% CI, 5.3 to 9.5 months; P = .50). However, ORR was significantly higher in patients receiving TMZ/veliparib compared with TMZ/placebo (39% v 14%; P = .016). Grade 3/4 thrombocytopenia and neutropenia more commonly occurred with TMZ/veliparib: 50% versus 9% and 31% versus 7%, respectively. Significantly prolonged PFS (5.7 v 3.6 months; P = .009) and OS (12.2 v 7.5 months; P = .014) were observed in patients with SLFN11-positive tumors treated with TMZ/veliparib. Conclusion Four-month PFS and median OS did not differ between the two arms, whereas a significant improvement in ORR was observed with TMZ/veliparib. SLFN11 expression was associated with improved PFS and OS in patients receiving TMZ/veliparib, suggesting a promising biomarker of PARP-inhibitor sensitivity in SCLC.

[1]  大堀 理,et al.  Memorial Sloan-Kettering Cancer Center , 2020, Definitions.

[2]  Y. Pommier,et al.  SLFN11 Blocks Stressed Replication Forks Independently of ATR. , 2018, Molecular cell.

[3]  David C. Smith,et al.  Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. , 2017, Cancer discovery.

[4]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[5]  Ying Feng,et al.  Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer , 2017, Oncotarget.

[6]  C. Rudin,et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.

[7]  A. Monks,et al.  Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression. , 2016, Journal of the National Cancer Institute.

[8]  Y. Pommier,et al.  Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition , 2016, Oncotarget.

[9]  C. Rudin,et al.  PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer , 2016, Clinical Cancer Research.

[10]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[11]  Yan Shi,et al.  Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors , 2015, Molecular Cancer Research.

[12]  T. Owonikoko,et al.  A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). , 2015, Lung cancer.

[13]  B. Wang,et al.  Trapping Poly(ADP-Ribose) Polymerase , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[14]  C. Rudin,et al.  Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes? , 2015, Clinical Cancer Research.

[15]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[16]  Yuan Qi,et al.  Clinical actionability enhanced through deep targeted sequencing of solid tumors. , 2015, Clinical chemistry.

[17]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Kelly,et al.  Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  S. Keir,et al.  Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program , 2014, Clinical Cancer Research.

[20]  A. Drilon,et al.  Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. , 2014, Lung cancer.

[21]  A. Ardizzoni,et al.  Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. , 2014, European journal of cancer.

[22]  J. Sarkaria,et al.  Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts , 2014, Clinical Cancer Research.

[23]  M. Berger,et al.  Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. , 2013, Journal of visualized experiments : JoVE.

[24]  Ying Feng,et al.  Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[25]  Michael Peyton,et al.  Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.

[26]  W. Reinhold,et al.  Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents , 2012, Proceedings of the National Academy of Sciences.

[27]  W. Curran,et al.  A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  C. Sima,et al.  Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker , 2012, Clinical Cancer Research.

[29]  Caroline Dive,et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Winer,et al.  A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. , 2010 .

[31]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[32]  P. Ellis,et al.  ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors , 2009, Clinical Cancer Research.

[33]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[34]  H. Mehdorn,et al.  A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis. , 2008, Analytical biochemistry.

[35]  Glenn Heller,et al.  Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[36]  J. von Pawel,et al.  Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  T. Ciuleanu,et al.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  L. Tentori,et al.  Chemopotentiation by PARP inhibitors in cancer therapy. , 2005, Pharmacological research.

[39]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[40]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[41]  J. Herman,et al.  Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.

[42]  P. Dollé,et al.  Poly(ADP-ribose) Polymerase-2 (PARP-2) Is Required for Efficient Base Excision DNA Repair in Association with PARP-1 and XRCC1* , 2002, The Journal of Biological Chemistry.

[43]  S. Gerson.  Clinical relevance of MGMT in the treatment of cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Minna,et al.  DNA methylation profiles of lung tumors. , 2001, Molecular cancer therapeutics.

[45]  L. Samson,et al.  Base excision repair in yeast and mammals. , 2000, Mutation research.

[46]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. , 2000, Cancer research.

[47]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[48]  J. Carmichael,et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. O'fallon,et al.  Stopping when the experimental regimen does not appear to help. , 1994, Statistics in medicine.

[50]  S S Ellenberg,et al.  An efficient design for phase III studies of combination chemotherapies. , 1985, Cancer treatment reports.